Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ciprofloxacin.

D K Terp, M J Rybak

    Drug Intelligence & Clinical Pharmacy
    |July 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Ciprofloxacin, a new antibiotic, shows broad-spectrum efficacy against resistant bacteria like MRSA and Pseudomonas. Clinical trials indicate low resistance development and minimal side effects, primarily gastrointestinal issues.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Multicenter Study of the Real-World Use of Ceftaroline versus Vancomycin for Acute Bacterial Skin and Skin Structure Infections.

    Antimicrobial agents and chemotherapy·2019
    Same author

    Impact of High-Level Daptomycin Resistance in the Streptococcus mitis Group on Virulence and Survivability during Daptomycin Treatment in Experimental Infective Endocarditis.

    Antimicrobial agents and chemotherapy·2017
    Same author

    Defining daptomycin resistance prevention exposures in vancomycin-resistant Enterococcus faecium and E. faecalis.

    Antimicrobial agents and chemotherapy·2014
    Same author

    Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA.

    Antimicrobial agents and chemotherapy·2013
    Same author

    Independent risk factors for the co-colonization of vancomycin-resistant Enterococcus faecalis and methicillin-resistant Staphylococcus aureus in the region most endemic for vancomycin-resistant Staphylococcus aureus isolation.

    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2013
    Same author

    Successful treatment of a left ventricular assist device infection with daptomycin non-susceptible methicillin-resistant Staphylococcus aureus: case report and review of the literature.

    Transplant infectious disease : an official journal of the Transplantation Society·2012
    Same journal

    Profile of prescription medication in a pediatric population.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    SI units in drug therapeutics.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Physicians' review of significant interventions by clinical pharmacists in inpatient care.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Possible interaction of ranitidine with phenytoin.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Famotidine-associated mental confusion in elderly patients.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Intravenous self-administration of elemental mercury: efficacy of dimercaprol therapy.

    Drug intelligence & clinical pharmacy·1988
    See all related articles

    Area of Science:

    • Pharmacology
    • Infectious Diseases
    • Bacteriology

    Background:

    • Ciprofloxacin is a novel fluorinated quinolone antibiotic.
    • It exhibits potent activity against Gram-positive and Gram-negative bacteria.
    • This includes challenging pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), Enterobacteriaceae, and Pseudomonas aeruginosa.

    Purpose of the Study:

    • To evaluate the efficacy and safety of ciprofloxacin in treating various infections.
    • To assess the development of bacterial resistance to ciprofloxacin.
    • To document the incidence and nature of ciprofloxacin-related adverse events.

    Main Methods:

    • Clinical trials were conducted using both oral and intravenous preparations of ciprofloxacin.
    • In vitro and in vivo studies were performed to investigate resistance patterns.

    Related Experiment Videos

  • Adverse events were systematically recorded throughout the trials.

    • Main Results:

    • Oral ciprofloxacin demonstrated effectiveness across a wide range of infections.
    • Intravenous ciprofloxacin is currently undergoing extensive clinical trials.
    • The incidence of resistant organisms was found to be very low.
    • Ciprofloxacin-related side effects were minimal, with gastrointestinal issues (e.g., nausea, vomiting) being most common.
    • Overall adverse experience incidence in global trials was approximately 6.4%.

    Conclusions:

    • Ciprofloxacin is an effective antibiotic with a favorable safety profile.
    • Its low incidence of resistance development makes it a valuable therapeutic option.
    • The antibiotic is well-tolerated, with a low rate of significant adverse events.